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SUMMARY
Hamartomatous polyposis syndromes are a rare group of
hereditary autosomal dominant disorders that comprise less than
1% of all hereditary colorectal cancers. However, these
hamartomatous polyposis syndromes have a malignant potential
for the development of colorectal cancer as well as extracolonic
cancers. The hamartomatous polyposis syndromes include juvenile
polyposis syndrome (JPS); PTEN hamartoma tumor syndrome, which
includes Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba
syndrome (BRRS), and Peutz-Jeghers syndrome (PJS). Due to the rarity
of these conditions, a thorough understanding of their clinical
presentation, including extraintestinal manifestations, and genetics is
important. For pediatric gastroenterologists, understanding how to
recognize and establish the appropriate diagnosis and cancer risk and
following appropriate screening and surveillance guidelines is crucial for
early detection to minimize the risk of carcinoma as children reach
adulthood.
Peutz-Jeghers syndrome (PJS) is an autosomal dominantly inherited
syndrome characterized by mucocutanoeus pigmentation, multiple
hamartomatous polyps in the gastrointestinal tract and an increased risk of
cancer at a young age. Inactivating germ-line mutations in the tumor
suppressor gene STK11/LKB1 have been detected in approximately 80%
of patients.
The aim of this work is to clarify the molecular basis of the disease in
Italian PJS patients.
We investigate the STK11/LKB1 gene mutations in a well-characterized
series of 9 unrelated Italian PJS patients, by using a combination of PCR,
RT-PCR, DNA sequencing, Southern blot analysis and real-time
polymerase chain reaction techniques.
We have characterized the specific STK11 mutation in 6 probands, and
identified 2 truncating mutations (1 novel and 1 known mutation), one
missense known mutation in the exon four, and two novel small in-frame
deletions in the exon six. Finally, we have found an intra-exonic in-frame
deletion encompassing exons 2 and 4: the possible mechanism leading to
this genomic rearrangement is most likely an Alu-Alu homologous
recombination.
In our study point mutations, small scale deletions/insertions and exonic
STK11 deletions account for about 67% of PJS; mutations in other
STK11 related genes examined have not be found. Other gene
inactivating methods, such as chromosomal rearrangements mediated by
Alu-Alu homologous recombination, which cannot be detected by
routinely molecular biology screening methods, might be responsible for
PJS in mutations negative population subset. However, the existence of
genetic heterogeneity cannot be excluded.
The “PTEN hamartomatous tumor sindrome” (PHTS), include a group af
syndromes that are caused by germline mutations of the tumor suppressor
gene PTEN (phosphatase and tensin homolog deleted on chromosome
ten). They belong to hamartomatous polyposis syndromes family, a rare
and  heterogeneous group of hereditary autosomal dominant disorders
characterized by multiple polyps in the gastrointestinal tract and greatly
increased risk of developing malignant tumours in multiple tissues.
The PTEN tumor suppressor gene affects multiple cellular processes
including cell growth, proliferation, and cell migration by antagonizing
phosphatidylinositol 3-kinase (PI3K)/Akt phatway.
we have first screened the PTEN coding region in three italian patients
with clinical diagnosis of PHTS by using a combination of RT-PCR,
direct sequencing of the amplified fragments and real-time polymerase
chain reaction techniques. Afterwards, in periferal blood cells of these
patients, we have defined the expression profile of other genes directly
related to PI3K/Akt phatway, as cMYC, COX2, CCND1 and TNFa, or
involved in colorectal cancer onset, as APC, DKC1 and hTERT.
We have characterized the specific PTEN mutation in 1 subject, the
c406C->T (C136R) mutation, a missence mutation of the catalytic
domain just described in literature before. The others two patients showed
a low level of PTEN mRNA expression, respectively of 0,3 and 0,4 fold
change, related to a healthy controls. All three patients were characterized
by an high level of COX2, TNFa and CCND1 genes expression and
decrease expression of APC gene.
Our data represent the first evidence of a PI3K/Akt phatway
dysregulation in periferal blood cells of PHTS patients that probably
determine a pro inflammation attivation. Knowledge of specific molecular
phatways costitutively dysregulated in this syndrome could be helpful in
optimizing molecular targeted therapy and preventative care.
RIASSUNTO
Le sindromi amartomatose sono un gruppo di disordini
autosomici dominanti molto rari, rappresentate  dalla poliposi
giovanile (JPS), dalla sindrome di Peutz-Jeghers (PJS), e dalle
sindromi amartomatose associate al gene PTEN (PHTS); queste
includono a loro volta la sindrome di Cowden (CS) e la sindrome
di Bannayan-Riley-Ruvalcaba (BRRS).
Pur essendo molto rare, esse sono tuttavia associate ad un aumento
significativo del rischio di sviluppare un tumore del colon, così
come di altri tipi di tumori extracolici, le cui sedi variano tra le
varie sindromi. Appare, quindi, evidente l’importanza di  poter
preventivamente diagnosticare,ciascuna sindrome al fine di
indirizzare i pazienti ad una specifica ed adeguata sorveglianza.
L’analisi molecolare dei geni candidati svolge un ruolo cruciale sia
nella diagnostica, che nella ricerca dei processi molecolari alla base
delle sindromi amartomatose. Inoltre lo studio delle alterazioni dei
pathways molecolari coinvolti nell’insorgenza di tali sindromi
rappresenta un importante mezzo, per chiarirne i meccanismi
molecolari e individuare nuovi e più mirati bersagli terapeutici.
A tal fine sono stati analizzati 9 pazienti affetti da sindrome di
Peutz-Jeghers e 3 soggetti affetti da sindrome di  Cowden
provenienti da altrettante famiglie non imparentate tra loro.
Mutazioni germinali nel gene oncosoppressore STK11/LKB1, che
codificano per una proteina della famiglia delle serine-treonine-
chinasi, la serina-treonina-chinasi 11 (STK11), sono responsabili
dell’insorgenza della PJS. La chinasi LKB1 fosforila ed attiva 14
chinasi a valle, attraverso le quali regola numerosi processi
cellulari tra cui quello apoptotico, della regolazione della
proliferazione cellulare, della polarità cellulare e della regolazione
del metabolismo.
Le mutazioni a carico del gene STK11/LKB1 rendono conto di una
percentuale di casi di PJS che varia tra il 30 e 70% ed è quindi di
grande importanza chiarire le basi molecolari dell’insorgenza della
malattia nei casi che non presentano mutazioni puntiformi a carico
del gene STK11/LKB1.
L’analisi molecolare della regione codificante del gene
LKB1/STK11, eseguita in 9 individui con diagnosi clinica di PJS ha
permesso l’identificazione e la caratterizzazione di tre mutazioni
non descritte in letteratura e di due già precedentemente descritte.
Nella nostra casistica la mutazione è stata identificata nel 60% dei
casi, coerentemente a quanto indicato in letteratura. Nei soggetti
affetti da PJS, negativi per la presenza di mutazioni puntiformi, nel
gene STK11 è stata effettuata un’analisi sia qualitativa che
quantitativa del messaggero utilizzando le tecniche di RT-PCR e di
real-time-RT-PCR. Per valutare la presenza di eventuali delezioni
intrageniche sono stati effettuati esperimenti di long-range PCR sul
DNA genomico e di Souther Blotting. I frammenti di peso
molecolare inferiore a quello atteso, evidenziati in seguito  ad
elettroforesi dei prodotti di PCR, sono stati caratterizzati mediante
sequenziamento diretto dei frammenti amplificati. In fine è stata
poi eseguita l’analisi in silico della sequenza del gene STK11/LKB1
utilizzando il programma RepeatMasker al fine di effettuare una
precisa localizzazione delle sequenze ripetute presenti all’interno
della sequenza genomica.
In uno dei soggetti analizzati è stata identificata, a livello del
messaggero, la perdita degli  esoni 2 e 3 Attraverso l’analisi di
sequenza è stato possibile identificare la presenza di due sequenze
Alu, appartenenti alla stessa sotto-famiglia (AluY), in
corrispondenza dei  “break-point” della delezione che si trovano
proprio all’interno della ripetizione di 26 coppie di basi che
costituisce il “core” di queste sequenze.
Nei tumori umani l’elevata densità di sequenze Alu è stata spesso
associata ad un’elevata frequenza di riarrangiamenti genomici,
quali delezioni o inversioni, che non sempre vengono rilevati
mediante le comuni tecniche di biologia molecolare, e che
potrebbero giustificare la percentuale di casi di PJS, nei quali non
viene identificata la specifica mutazione a carico del gene
STK11/LKB1.
La sindrome di Cowden è dovuta a mutazioni nel gene
oncosopressore PTEN, che codifica per una proteina con attività
tirosina-fosfatasica che determina l’inibizione della via PI3K/Akt.
I pazienti affetti da noi analizzati, presentavano caratteristiche
fenotipiche tipiche di tale sindrome. L’analisi molecolare è stata
condotta mettendo a punto in primo luogo una reazione di RT-
PCR e sequenza diretta del prodotto di PCR, a cui
successivamente è seguita la valutazione dei livelli di espressione
del messaggero del gene PTEN. In uno dei tre pazienti è stata
dunque identificata una mutazione puntiforme a livello dell’esone
5 del gene, successivamente confermata mediante amplificazione e
sequenziamento diretto sul DNA genomico del soggetto. A questa
prima analisi è seguita la quantizzazione relativa dei livelli
d’espressione del gene, effettuata mediante real-time PCR, che ha
evidenziato una marcata diminuzione di espressione del gene
PTEN nei due pazienti negativi per la presenza di mutazioni nella
regione codificante del gene.
Infine, per meglio comprendere i meccanismi molecolare coinvolti
nell’insorgenza delle sindromi PHTS, è stato effettuato uno studio
sui livelli di espressione di alcuni geni correlati al pathway
molecolare PI3K/Akt o comunque coinvolti nell’insorgenza dei
CRC, quali APC, cMYC, CCND1, COX-2 e TNF, in linfociti
estratti da sangue periferico. Tale analisi ha evidenziato un
significati aumento nell’espressione nei pazienti affetti da CS
dell’espressione della COX-2, CCD1 e TNF, mentre risulta
diminuita l’espressione del gene APC. Queste indicazioni, che
certamente necessitano di ulteriori approfondimenti,
rappresentano però la prima evidenza di una possibile attivazione
del pathway  PI3K/Akt in linfociti di sangue periferico
provenienti da pazienti con mutazioni del gene PTEN. Mutazioni
di tale gene dunque determinare un’attivazione molto precoce di
segnali pro-infiammatori che a lungo andare possono alterare la
crescita cellulare, spingendo così la cellula verso la trasformazione
neoplastica.
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INTRODUCTION
A more individualized approach to cancer treatment and prevention will
depend upon the ability to identify and understand the molecular changes
that drive the tumorigenic process in each individual tumor. The
advancement of DNA sequencing technologies spurred by the human
genome sequencing project is allowing researchers to determine how
many somatic mutations exist in a given tumor (Heinen C. D., 2009). The
number of mutations may be as high as 80 or more (Sjoblom T. et al.,
2006; Wood L.D. et al., 2007) or it may be as small as eight to ten (Ley
T.J. et al., 2008); these differences likely are due to the tumor type, the
methods involved for detecting alterations and the threshold for predicting
whether an alteration is significant to phenotype. Determining which
variations drive tumor phenotype will depend upon an ability to ascertain
the cellular function affected by each somatic change. The relationship
between genotype to phenotype remains the great challenge of basic
cancer research and the key to developing effective targeted therapies.
Nothing, perhaps, demonstrates this challenge better than contemplating
how much, yet how little, we understand about the relationship between
genotype and phenotype in hereditary colorectal cancer (CRC) (Heinen C.
D., 2009). Because of the high frequency of cases in the population, of the
ability to identify and isolate benign precursor lesions in the colon, and of
hereditary diseases with increased predisposition to CRC development,
colon cancer has been one the most studied cancers and it serves as a
model for understanding basic principles of tumorigenesis that may apply
to all tumor types (Fearon E.R., Vogelstein B., 1990).
More than 1 million new cases of colorectal cancer (CRC) are diagnosed
worldwide each year. The CRC is the 3rd most common malignancy and
the 4th most common cause of cancer mortality worldwide. (Tenesa A. et
al. 2009).
Approximately 5% of CRC cases are associated with highly penetrant
inherited mutations and clinical presentations that have been well-
characterized. Kindred and twin studies estimated that approximately
30% of all CRC cases are an inherited form of the disease, are not
completely understood. They are likely to be caused by alterations in
single genes that are less penetrant but more common than those
associated with the well-characterized syndromes. Inherited CRCs are
also likely to be caused by alterations in multiple susceptibility loci that
have additive effects. A precise understanding of the genetics of inherited
CRCs is important for identifying at-risk individuals, improving cancer
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surveillance and prevention strategies, and developing better diagnostic
and therapeutic approaches. (Lichtenstein P, et al. 2000; Grady WM.
2003).
Between 2% to 5% of all colon cancers arise in the setting of well-defined
inherited syndromes. Each is associated with a high risk of colon cancer.
Clarification of predisposing genes allows for accurate risk assessment
and more precise screening approaches. (TAB 1). The syndromes of CRC
are defined on the basis of clinical, pathological, and, more recently,
genetic findings. Conditions that express adenomatous polyps include
Lynch syndrome (also called hereditary nonpolyposis colorectal cancer)
familial adenomatous polyposis (FAP), and MUTYH-associated
polyposis (MAP) (Jasperson KW et al., 2010).
Lynch syndrome, accounting for 2%–4% of all CRCs (Stoffel E, et al.
2009), is the result of a germline mutation in a class of genes involved in
DNA Mismatch Repair (MMR), including hMSH2, hMLH1, hMSH6, and
hPMS2, and it is  characterized by a high level of microsatellite instability
(MSI-H). The lifetime risk is 40%–60%, and it  is many greater than the
estimated risk for CRC in general population. Lynch syndrome is also
responsible for approximately 2% of all endometrial cancers (Hampel H.
et al, 2006).
FAP is the second-most common inherited CRC syndrome, with a
prevalence of 1 in 10,000 individuals. Characteristic features of FAP
include development of hundreds to thousands of colonic adenomas
beginning in early adolescence, and inevitable CRC in untreated
individuals. The average age of CRC diagnosis if untreated is about 39
years; nearly 7% develop CRC by age 21 and about 95% by age 50. FAP
and attenuated FAP are caused by germline mutations in APC gene ,
which encodes a tumour suppressor that is part of the WNT signalling
pathway. The characterization of APC mutation in a proband confirms the
diagnosis, allowing precise identification of at risk-relatives who have
inherited the disease (Jasperson KW et al., 2010). Hamartomatous polyps
are the primary lesions in hamartomatous syndromes; they include
juvenile polyposis syndrome (JPS), PTEN hamartoma tumor syndrome,
which includes Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba
syndrome (BRRS); and Peutz-Jeghers syndrome (PJS). Finally,
hyperplastic polyposis (HPP) is an unusual condition that has a
substantial cancer risk and must be distinguished from the other
conditions. All of these conditions are inherited, autosomal-dominant
disorders, except MYH associated polyposis (MAP), which is autosomal-
recessive, and HPP, which is rarely inherited. Attenuated FAP is
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associated with small number of adenomas so his phenotype can be
confused with Lynch syndrome, or sporadic polyps. Although clinical
similarities do exist, each syndrome has distinct cancer risks,
characteristic clinical features, and separate genetic etiologies.  Diagnosis
and management recommendations are based on these divergent features
(Jasperson KW et al., 2010).
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Table 1: Hereditary colon cancer syndromes
JP, juvenile polyps; HP, hyperplastic polyps; PJ, Peutz–Jeghers; BRRS,
Bannayan–Ruvalkaba–Riley syndrome;CHRPE, congenital hypertrophy of the
retinal pigment epithelium; CRC, colorectal carcinoma; SCTAT, sex cord tumors
with annular tubules; AD, autosomal dominant; AR, autosomal recessive; ?,
unknown at present; DD, differential diagnosis; *1 HNPCC and BHD are not
themselves polyposis syndromes, but are included in the DD of polyposis
syndromes. According to recent studies, BHD is not associated with intestinal
polyps;
From: Arztebl Int. 2010 March; 107(10): 163–173.
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1.1 Hereditary Hamartomatous Polyposis Syndromes.
Hamartomatous polyposis syndromes are a rare group of hereditary
autosomal dominant disorders that comprise less than 1% of all hereditary
colorectal cancers. (Wirtzfeld DA et al., 2001) Hamartomatous polyps are
benign entities comprised of cells that are indigenous to the area in which
they are found (ie, all cell layers with a mesenchymal predominance).
However, these hamartomatous polyposis syndromes have a malignant
potential for the development of colorectal cancer as well as extracolonic
cancers. The progression of hamartomatous polyps to carcinoma is still
being elucidated. Unlike adenomatous polyps, in which malignant
transformation progresses through the adenoma-carcinoma sequence via a
gatekeeper or caretaker defect, in hamartomatous polyps, a proposed
hamartoma-carcinoma sequence hypothesis involves a landscaper defect
in which stromal elements create a local environment that promotes
epithelial dysplasia and ultimately leads to carcinoma (Kinzler KW et
al.,1998). The hamartomatous polyposis syndromes include juvenile
polyposis syndrome (JPS); PTEN hamartoma tumor syndrome, which
includes Cowden syndrome (CS) and Bannayan-Riley-Ruvalcaba
syndrome (BRRS), and Peutz-Jeghers syndrome (PJS). Due to the rarity
of these conditions, a thorough understanding of their clinical
presentation, including extraintestinal manifestations, and genetics is
important. For pediatric gastroenterologists, understanding how to
recognize and establish the appropriate diagnosis and cancer risk and
following appropriate screening and surveillance guidelines is crucial for
early detection to minimize the risk of carcinoma as children reach
adulthood (Manfredi M, 2010).
Juvenile polyps are the most common type of pediatric gastrointestinal
polyps. Solitary juvenile polyps can develop at any age, though they
appear most frequently in preschool children and have an incidence of 2%
in children under 10 years of age. In JPS, affected individuals develop
multiple gastrointestinal juvenile polyps, predominantly in the colon,
though the condition may also affect the rest of the gastrointestinal tract
(Desai DC. Et al., 1995). Multiple extraintestinal manifestations have
been reported in approximately 11–20% of cases with JPS, and they can
include heart defects, polydactyl, clubbing, intestinal malrotation, Meckel
diverticulum, hydrocephalus, macrocephaly, hypertelorism, cleft lip, cleft
palate, double renal pelvis and ureter, bifid uterus and vagina,
undescended testes, and supernumery teeth. (Chow E. et al. 2005)
Individuals with JPS are at risk for the development of colorectal, gastric,
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small intestinal, and pancreatic cancers. The risk of developing colorectal
cancer from solitary juvenile polyps is thought to be negligible or
nonexistent. However, individuals with JPS are at risk for developing
adenomatous change and carcinoma. The incidence of colorectal cancer
has been reported to be to 20%, with a mean age of 34 years (age range,
15–59 years) and an estimated cumulative colorectal cancer risk of 68%
by 60 years of age (Schreibman IR. et al., 2005). The surveillance
protocol for this disease recommends the continue screening until 70
years of age if a genetic mutation is found, and no polyps are detected at
the time of the initial endoscopy; however, if no genetic mutation is found
and no polyps are detected at the initial endoscopy, repeat endoscopy
should be performed every 1–2 years until 35 years of age. (Manfredi,
2010).
The PTEN hamartoma tumor syndromes (PHTS) are a collection of rare
clinical syndromes characterized by germline mutations of the tumor
suppressor PTEN (phosphatase and tensin homolog deleted on
chromosome 10. They includes Cowden’s syndrome (OMIM 158350),
Bannayan–Riley–Ruvalcaba syndrome (OMIM 153480), and all
syndromes that are caused by germline mutations of the tumor suppressor
gene PTEN (Wirtzfield et al. 2001). The PHTS are a spectrum of
syndromes with variable clinical manifestations characterized by aberrant
growth. Hamartomas are a histologically distinct subtype of benign
tumors in which cells maintain normal differentiation but are disorganized
with respect to architecture. Cowden syndrome (CS) is the prototypic
syndrome, characterized by mucocutaneous lesions, benign hamartomas,
macrocephaly, and increased predisposition to breast, thyroid, and
endometrial carcinoma. Lhermitte–Duclos (LD), a variant of CS, is
characterized by dysplastic gangliocytomas of the cerebellum, which can
lead to hydrocephalus, ataxia, and seizures (Hobert JA, Eng C., 2009). CS
is an autosomal dominant syndrome, with a reported incidence of 1 in
200,000 individuals. This most likely remains an underestimation, as CS
is associated with a high degree of phenotypic variability and its hallmark
features are under-recognized within the medical community (GM
Blumenthal and PA Dennis 2008). Hamartomatous polyps throughout the
gastrointestinal tract are associated with this syndrome but are not as
common as the extraintestinal findings associated with the syndrome,
Gastrointestinal polyps in CS are typically asymptomatic, and can occur
anywhere in the GI tract, with colonic polyps present in 60–90% of
patients. Their incidence varies in the literature, ranging anywhere from
30% to 85% (Marra C. et al. 1994; Starink TM, et al. 1986). It is
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generally thought that the incidence of gastrointestinal polyps in CS is
less than that of BRRS, though this belief is debated in the literature.
Benign thyroid lesions occur in up to 75% of patients with CS, including
adenomas, hamartomas, multinodular goiter, and Hashimoto’s thyroiditis.
Up to half of women with CS are afflicted with benign breast disease,
which can be extensive and bilateral. Cowden syndrome patients are at
increased risk to develop breast, thyroid, and endometrial cancer. The
lifetime risk of breast cancer in women with CS is estimated to be as high
as 50%, as compared to 11% within the general population. In addition to
breast, thyroid, and endometrial cancers, other malignancies have
anecdotally been reported to be increased with CS, including melanoma,
renal cell carcinoma, and gliomas (Eng C, 2003).
Bannayan–Riley–Ruvalcaba sindrome is characterized by macrocephaly,
benign hamartomas, pigmented macules of the glans penis, lipomas,
hemangiomas, and the developmental delay, or mental retardation. Other
phenotypic features of BRRS disorder include thyroid abnormalities such
as Hashimoto’s thyroiditis, high-arched palate overgrowth of prenatal or
postnatal onset, macrosomia, hypotonia, joint hyperextensibility,
downward slanting palpebral fissures, frontal bossing, hypoglycemia,
seizures, and cafe´ au lait spots. These phenotypic features are highly
variable, although they appear to cluster within a given family. There is
significant phenotypic overlap between CS and BRRS with common
features including hamartomas, macrocephaly, and thyroid abnormalities.
Interestingly, identical PTEN mutation shave been found in patients who
present with phenotypic manifestations characteristic of either BRRS or
CS. Even individuals within a single family that have the same germline
PTEN mutation can have phenotypic features more consistent with either
BRRS or CS. Same authors  have suggested that BRRS and CS represent
a single disorder with variable phenotypic expression and age-related
penetrance, and have questioned whether the distinction between BRRS
and CS is clinically relevant. (Pilarski R, Eng C., 2004)
Peutz–Jeghers syndrome (OMIM 175200) is an autosomal dominant
hamartomatous polyposis syndrome characterized by melanotic
mucocutaneous hyperpigmentation and GI hamartomas, which occur
anywhere from the stomach to the anus with a prevalence of
approximately one in 200,000. The pigmentation, by melanin, has the
appearance of freckle-like spots on the face, lips, mouth, and anal region,
presenting in more than two thirds of patients with PJS (Winship IM,
2008). The numbers of polyps present in each case are usually fewer than
20, and these polyps vary in size from several millimeters to more than 5
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cm in diameter. In contrast to JPS, in which the polyps occur in the colon,
Peutz–Jeghers hamartomatous polyps are most prevalent in the small
intestine (64%), but they may also be present in the colon (53%), the
stomach (49%), and rectum (32%). The disease, associated with
inactivating mutations in lkb1/Stk11 gene, has variable penetrance, even
within families; some patients only manifest with hyperpigmentation,
while others may manifest with both pigmentation and intestinal polyps
(McGarrity TJ, Amos C 2006). The diagnosis of PJS is based upon
clinical findings and the histologic appearance of the polyps. Individuals
with PJS are at risk for the development of colorectal, gastric, small
intestinal, esophageal, and pancreatic cancers. PJS patients are also at risk
for extraintestinal cancer such as lung, breast, ovarian, testicular, and
endometrial cancers. A meta-analysis showed that the risk of developing
any type of cancer by 64 years of age was 93% (relative risk of 15) and
found that the relative risk of developing any type of cancer was 47% by
65 years of age in PJS patients with known genetic mutations in
LKB1/STK11. More recently, a study looking at 419 PJS patients, 297 of
whom had documented mutations, showed the risk of cancer to be 60%
by 60 years of age and 85% by 70 years of age. This same study reported
the risks of developing gastrointestinal cancer (31%), breast cancer
(31%), gynecologic cancer (18%), pancreatic cancer (7%), and lung
cancer (13%) by 60 years of age. Individuals with PJS are also at risk for
developing rare sex cord tumors. Women are at risk for sex cord tumors
with annular tubules that are benign, and men are at risk for developing
Sertoli cell tumors, which result in feminization (Jasperson KW, et al.
2010).
1.2 Genetic of the Hereditary Hamartomatous Polyposis Syndromes.
Juvenile polyposis syndrome (JPS) has been commonly associated with
three genes: SMAD4, BMPR1A, and ENG, all of which are part of the
transforming growth factor-β (TGFβ) superfamily of proteins. The
SMAD4 gene, located on chromosome 18q21.1, was first identified;
germline mutations in the SMAD4 gene have a prevalence of 20% in JPS
patients. (Jasperson KW, et al. 2010). Patients with the SMAD4 mutation
are more likely to have upper gastrointestinal polyps. Multiple types of
mutations have been reported in the SMAD4 gene, including missense,
nonsense, deletions, and insertions; however, the most common mutation
is the 4-base pair deletion in exon 9.
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The bone morphogenetic protein receptor type IA (BMPR1A) gene is
located on chromosome 10q22-23 and was reported by Howe and co-
worker in 2001. (Howe JR et al. 2001). Germline mutations in the
BMPR1A gene have a prevalence of 20% in JPS patients. Mutations of the
endoglin gene (ENG) have recently be identified in 2 patients with JPS;
however, its role as a predisposition gene still requires additional
confirmation. The ENG gene is located on chromosome 9q34.1.47 ENG
encodes the protein endoglin, which is an accessory protein of the TGF-β
signalling pathway (Jasperson KW, et al. 2010).
The involvement of the PTEN gene mutation in patients with juvenile
polyposis is a controversial topic, they are present in five percent of
familial JPS which initially led to speculation that PTEN mutations might
lead to some cases of JPS. However, upon further study, it was found that
these patients had unrecognized Cowden’s syndrome (Howe JR et al.
2001; Eng C. 2001).  This finding may not exclude PTEN involvement in
some cases of JPS, and it might indicate a biological synergy of the
BMPR1A and PTEN genes. In addition, several infants with very
aggressive phenotype of JPS, characterized by generalized polyposis and
often diagnosed before 2 years of age, were found to have germline
deletions that encompass both PTEN and BMPR1A. These children’s
clinical manifestations often overlap with those seen in Cowden’s
syndrome or Bannayan– Riley–Ruvalcaba syndrome (BRRS). Given the
high occurrence of breast and thyroid neoplasms in patients with
Cowden’s syndrome, the screening for these cancers should be
undertaken if a PTEN mutation is identified in JPS patients (Hui-Min
Chen & Jing-Yuan Fang 2009).
Approximately 85% of patients with Cowden syndrome and more than
60% of patients with BRRS were noted to carry germline mutations in the
PTEN tumor suppressor gene, located on chromosome 10q23 (Eng C.
2000). The PTEN protein inhibits cell growth and proliferation by acting
as a negative regulator of the AKT pathway (Zhou XP, et al. 2003) and
somatic PTEN mutations are prevalent in various malignancies (Eng C.
2003). Mutations have been detected in the promoter region of PTEN in
patients with Cowden’s syndrome, whereas deletions of all or part of
PTEN (not normally detectable by conventional polymerase chain
reaction) have been documented in patients with BRRS. Several BRRS
patients do not have a PTEN mutation; however, it has recently been
demonstrated that a significant proportion of these patients have germline
PTEN deletions. Therefore, point mutations or deletions in the different
regions of the PTEN gene might be corresponding to the different levels
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of possibility of developing BRRS or Cowden’s syndrome. Until recently,
no gene mutation for Proteus syndrome has been identified. Although
mouse models of PTEN deficiency are available, their function in helping
to dissect the pathogenesis of human PHTS syndrome is limited.
Heterozygous PTEN +/− mice often develop thymic and peripheral
lymphomas and prostate cancer at a young age. They also develop
hamartomatous polyps of the gastrointestinal tract, but the spectrum of
neoplasia and malignancies observed bears little resemblance to that seen
in cases of human PHTS syndrome (Chen H and Fang J, 2009).
Germline mutations in the serine/threonine kinase 11 gene
(STK11/LKB1) are documented in approximately up to 70-80% of the
PJS patients; of these about 15% have germline deletions in all or part of
the gene. (Volikos E, et al. 2006; Aretz S, et al 2005; Hearle NC, 2006) In
the remaining 20-30 % of PJS patients, defects in other genes or not yet
identified ways of LKB1 inactivation might be responsible for PJS.
Several putative candidate genes have been studied, including genes
encoding LKB1 interacting proteins; so far a second PJS gene has not
been identified. (Alhopuro P et al. 2005). The STK11 gene is localized on
chromosome 19 at position p13.3, spans 23 Kb in the genome and
includes 10 exons, of which, nine are coding exons and 1 is an
untranslated exon localized at 3’-UTR. (Hemminki A, Tomlinson I, et al.
1997). It is an ubiquitously expressed gene encoding a serine/threonine
kinase involved in the transduction of intracellular growth signals.
LKB1/STK11 has an essential role in G1 cell cycle arrest, cell polarity,
p53-dependent apoptosis, and cellular energy levels. (Manfredi M., 2010).
Genotype–phenotype correlation suggests that patients with PJS, who
have a truncating mutation in STK11/LKB1, have a significantly earlier
age of onset than those who have a missense mutation or when no
mutation is detected in STK11/LKB1 (Amos CI, et al. 2004). A follow-up
study on patients with PJS who had a germline mutation in this tumor
suppressor gene confirmed that these patients have a very high risk of
developing cancer (Chen H and Fang J, 2009).
1.3 Hamartomatous Syndromes and their molecular pathways.
Transforming growth factor beta (TGF-β) patway in hamartomatous
syndromes:
The TGF-β signalling pathway is involved in the control of several
biological processes, including cell proliferation, differentiation,
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migration and apoptosis (Massague J. et al., 2000) (Fig.1). It is one of the
most commonly altered cellular signalling pathways in human cancers
(Elliott RL, Blobe GC., 2005). TGF-β signalling is activated by the
binding of TGF-β ligands to type II TGF-β receptor (TGFBR2). Three
TGF- β isoforms (TGFB1, TGFB2 and TGFB3) are expressed in
mammalian epithelium, and each is encoded by a unique gene and
expressed in both a tissue-specific and developmentally regulated manner.
TGFB1 is the most abundant and ubiquitously expressed isoform. Once
TGFBR2 bound to TGF-β, recruits and phosphorylates the type I TGF-β
receptor (TGFBR1), which stimulates TGFBR1 protein kinase activity.
Activated TGFBR1 phosphorylates two downstream transcription factors,
SMAD2 and SMAD3, allowing them to bind to SMAD4.  BMPR1A is a
type 1 serine/threonine kinase receptor protein that is bound to a type II
serine/threonine kinase receptor protein; it acts upstream of SMAD4,
phosphorylates SMAD proteins that then bind to SMAD4. The resulting
binds SMAD complexes translocate into the nucleus and interact with
other transcription factors in a cell-specific manner to regulate the
transcription of a multitude of TGF-β-responsive genes (Elliott RL, Blobe
GC., 2005). It is increasingly apparent that TGF-β-related proteins initiate
the activation not only of SMADs but also of other signalling pathways.
These pathways regulate SMAD-mediated responses and also induce
SMAD-independent responses. Some of the downstream targets of TGF-β
signalling are important cell-cycle checkpoint genes, including CDKN1A
(p21), CDKN1B (p27) and CDKN2B (p15), and their activation leads to
growth arrest (Derynck R, Zhang YE, 2003). Therefore, TGF-β serves as a
tumor suppressor in the normal intestinal epithelium by inhibiting cell
proliferation and inducing apoptosis. Many colorectal cancers escape the
tumor-suppressor effects of TGF-β and are resistant to TGF-β-induced
growth inhibition (Derynck R, Zhang YE, 2003). However, during the late
stages of colorectal carcinogenesis, TGF-β acts as a tumor promoter and
is usually highly expressed. High levels of TGFB1 in the primary
colorectal tumor are associated with advanced stages and a greater
likelihood of recurrence and decreased survival (Xu Y, Pasche B., 2007).
Experimentally, prolonged exposure to high levels of TGF-β promotes
neoplastic transformation of intestinal epithelial cells and TGF-β
stimulates the proliferation and invasion of poorly differentiated and
metastatic colon cancer cells (Sheng H, et al. 1999). Although the
mechanism by which TGF-β switches its growth inhibitory effect into
growth stimulatory effect is not well understood, TGF-β has been shown
to increase the production of several mitogenic growth factors including
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TGF-α, FGF and EGF. In addition, TGF-β can activate SMAD-
independent pathways, such as Ras/MAPK pathway, JNK pathway and
PI3 kinase/Akt pathway (Elliott RL, Blobe GC., 2005). Thus, TGF-β may
drive the proliferation of colorectal cancer cells in conjunction with these
oncogenic pathways. TGF-β is also a potent regulator of cell adhesion,
motility and the extracellular matrix composition, which are involved in
tumor invasion and metastasis. In addition, TGF-β signalling promotes
angiogenesis and immuno-suppression (Elliott RL, Blobe GC., 2005).
Therefore, it is likely that cancer cells achieve resistance to the tumor-
suppressor effects of TGF-β but remain responsive to the tumor-promoter
effects of TGF-β via selective alterations of this signalling pathway (Xu Y,
Pasche B., 2007).
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Figure 1: TGF molecular pathways.
Introduction
14
PI3K/PTEN/AKT Pathway:
Phosphoinositide 3-kinase (PI3K) plays a crucial role in effecting
alterations in a broad range of cellular functions in response to
extracellular signals. A key downstream effector of PI3K is the serine-
threonine kinase Akt which, in response to PI3K activation,
phosphorylates and regulates the activity of a number of targets, including
kinases, transcription factors and other regulatory molecules (Fig. 2) . A
major role for PI3K pathway activation in human tumors has been more
recently established following both the positional cloning of the PTEN
tumor suppressor gene, and the discovery that the PTEN protein product
was a lipid phosphatase that antagonizes PI3K function and consequently
inhibits downstream signalling through Akt. Subsequently a number of
the components of the pathway have been found mutated or deregulated
in a wide variety of human cancers highlighting the key role of this
pathway in cellular transformation.
PI3K belongs to a large family of PI3K-related kinases or PIKK. Other
members of the family include mTOR (mammalian target of rapamycin),
ATM (ataxiatelangiectasia mutated), ATR (ATM and RAD3 related),
DNA-PK (DNA-dependent protein kinase). All possess the characteristic
PI3K-homologous kinase domain and a highly conserved carboxyl-
terminal tail (Kuruvilla & Schreiber, 1999). However, only PI3K is
known to have an endogenous lipid substrate. Importantly, all members of
the PIKK family have been implicated in human cancer both as
oncogenes, this is the case of type I PI3K or as tumor suppressor genes in
the case of ATM and ATR. The PI3K family comprises eight members
divided into three classes according to their sequence homology and
substrate preference (Fruman et al., 1998; Vanhaesebroeck & Waterfield,
1999). All mammalian cells express representatives of the three groups.
PTEN (phosphatase and tensin homolog deleted on chromosome
10)/MMAC1 (mutated in multiple advanced cancers)/TEP-1(TGFb-
regulated and epithelial cell enriched phosphatase) antagonizes signalling
through the PI3K pathway. Indeed, cells lacking PTEN function exhibit a
two fold increase in PtdIns-3,4,5-P3 levels (Stambolic et al., 1998). PTEN
can also dephosphorylate tyrosine-, serine-, and threonine-phosphorylated
peptides (Myers & Tonks, 1997). This activity may be related to
regulation of cell adhesion and spreading. Literature findings suggest that
this activity is not sufficient to block tumor development. Indeed, the
preponderance of the published data suggests that PTEN’s role as a tumor
suppressor is mediated largely through its lipid phosphatase activity.
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The serine-threonine protein kinase Akt (also known as protein kinase B,
PKB) mediates many of the downstream effects of PI3K and
consequently plays a central role in both normal and pathological
signalling by the PI3K pathway. There are three closely related enzymatic
isoforms Akt1 (PKBa), Akt2 (PKBb)and Akt3 (PKBg), they are similar
both in structure and size and are thought to be activated by a common
mechanism. To date, no differences in substrate preference have been
established are currently assumed to have identical or similar substrate
specificity. The three isoforms are widely expressed though Akt3 tissue
distribution seems to be more restricted than 1 and 2, being primarily
expressed in brain and testis (Okano, et al. 2000).
Activation of Akt is a multi-step process involving both membrane
binding and phosphorylation. Upon PI3K activation and production of
PtdIns-3,4,5-P3 and PtdIns-3,4-P2, Akt is recruited to the plasma
membrane where it binds to these phosphoinositides through its PH
domain. Activation is then thought to involve a conformational change
and phosphorylation on two residues. Growth factor stimulation of PI3K
activity leads to Akt activation. Conversely, PI3K inhibition (i.e. using
chemical inhibitors such as wortmannin or LY294002) and PTEN
mediated dephosphorylation of PtdIns-3,4,5-P3 and PtdIns-3,4-P2 results
in inhibition of Akt. After activation, Akt can phosphorylate a number of
substrates both in the cytoplasm and in the nucleus.
Akt phosphorylates a variety of substrates involved in the regulation of
key cellular functions, including cell growth and survival, glucose
metabolism and protein translation. These targets include GSK3, IRS-1
(insulin receptor susbtrate-1), PDE- 3B (phosphodiesterase-3B), BAD,
human caspase 9, Forkhead and NF-kB transcription factors, mTOR,
eNOS, Raf protein kinase, BRCA1, and p21Cip1 /WAF1 (Altiok et al.,
1999; Montagnani, et al., 2001; Zhou et al., 2001; Zimmermann &
Moelling, 1999). One common mechanism through which Akt-mediated
phosphorylation results in substrate inhibition is through the regulation of
subcellular localization by interaction with 14-3-3 proteins (i.e. BAD,
forkhead transcription factors). 14-3-3 proteins are cytoplasmic proteins
that bind specifically to phosphoproteins and retain them in the cytoplasm
away from their targets. In particular the Akt consensus phosphorylation
site is also a consensus 14-3-3 binding site (Yaffe et al., 2001).  FKHR,
FKHRL1 and AFX transcription factors (henceforth referred to as
Forkhead) belong to the winged helix/forkhead transcription factors
family characterized by a 100-amino acids, monomeric DNA binding
domain (DBD) (Kops & Burgering, 1999; Kops et al., 1999). These three
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family members are directly phosphorylated and regulated by Akt. In
cancer cell lines lacking functional PTEN, FKHRL1 and FKHR are
constitutively phosphorylated by Akt and are hence constitutively
cytoplasmic and unable to activate transcription. Thus, Forkhead is a
critical effector of both cell-cycle progression and apoptosis downstream
of PTEN (Nakamura et al., 2000). In addition, other Forkhead family
members have also been implicated in the induction of apoptosis both
through the upregulation of FasL (Brunet et al., 1999) and through the
regulation of the pro-apoptotic Bcl-2 interacting mediator (Bim1)
(Dijkers, et al. 2000). Human Caspase-9, a member of the protease family
intimately associated with the initiation of apoptosis, is thought to be
phosphorylated and inhibited by Akt. (Cardone et al., 1998). However,
the Akt phosphorylation site is not conserved in the Capase 9 proteins
from other mammals making its in vivo importance unclear.  In addition
to the inhibition of pro-apoptotic factors, Akt can also activate the
transcription of anti-apoptotic genes through the activation of the
transcription factor NFkB. When bound to its inhibitor, termed IkB,
NFkB localises to the cytoplasm. Akt associates and activate the IkB
kinases (IKKs). Activated IKKs phoshorylate IkB targeting it for
degradation by the proteosome. This allows NFkB to translocate to the
nucleus and activate transcription of a variety of substrates including anti-
apoptotic genes such as the inhibitors of apoptosis (IAP) c-IAP1 and 2
(Kane, et al 1999; Romashkova & Makarov, 1999).
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Figure 2:PI3K/PTEN/AKT Pathway
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Recent data indicate that serine/threonine protein kinase Akt (Akt)
signalling cooperates with Wingless (Wnt) to activate -catenin in
intestinal stem and progenitor cells through phosphorylation at Ser552 (P-
-catenin552). The  phosphorylation at Ser552 was associated with the
transcriptional activation. This activation impaires the -catenin
degradation translocates to the nucleus where it binds Tcell
factor/lymphoid enhancing factor and initiates transcription of Wnt target
genes such as c-myc and cyclin- D1. Nuclear accumulation of -catenin is
a hallmark of activated canonical Wnt/-catenin signalling. PI3K-
mediated generation of PI-3,4,5-triphosphate recruits Akt for activation of
proliferation and survival signalling. He et al15 reported that Phosphatase
and tensin homolog (PTEN) deficiency increased PI3K/Akt activation,
resulting in excessive proliferation and crypt fissioning within small-
bowel (SB) polyps.
Reduced -catenin degradation and enhanced nuclear localization of
stabilized -catenin are key events in stem cell activation in a variety of
systems including the intestine, Phosphatidylinositol 3-kinase
(PI3K)/serine/threonine protein kinase Akt (Akt) signalling, in fact has
been proposed to induce proliferative signals in intestinal epithelial cells
(IECs). Recent studies suggest PI3K/Akt signalling is up-regulated in
crypt IECs; in chronic ulcerative colitis (CUC) and active Crohn’s disease
(CD) indicating a probable involvement of this pathway in the
inflammation. .
PI3K-induced and Akt-mediated -catenin signalling are required for
progenitor cell activation during the progression from CUC to colitis-
associated cancer  (CAC); these factors might be used as biomarkers of
dysplastic transformation in the colon (Lee G, et al.  2010)
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Figure 3: Link between PI3K/AKT and WNT pathways -catenin-
mediated.
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The LKB1 Pathway:
LKB1 serves to activate AMPK by direct phosphorylation of Thr172 in
its activation loop, which is essential for AMPK catalytic activity.
AMPK, a cellular energy sensor, functions as a master regulator of
cellular energy metabolism. Depletion of intracellular ATP levels due to
either physiological stimuli such as exercise and muscle contraction or
pathological stresses such as hypoxia, oxidative stress and glucose
deprivation, activate AMPK (Fig. 4). AMPK functions to restore
intracellular ATP levels by inhibiting ATP-consuming processes such as
protein translation and cell growth; moreover promotes ATP-generating
processes such as gluconeogenesis and lipogenesis. Thus, under energy
starvation AMPK inhibits cell proliferation by directly phosphorylating
TSC2 and enhancing its ability to switch off mTORC1 signalling.
Mutational inactivation of LKB1 results in hyperactivation of mTORC1
signalling under low energy conditions, suggesting that LKB1 is required
for repression of mTORC1 in a AMPK- and TSC2-dependent manner.
(Krymskaya1, V.P. and  Goncharova E.A. 2009)
In addition to the involvement in energy metabolism, LKB1 has the
capacity to regulate multiple cellular processes, such as cell cycle arrest,
Wnt signalling, transforming growth factor beta signalling and chromatin
remodelling.
LKB1 forms a complex with pseudokinase STRAD and the scaffolding
protein MO25,(Baas AF,2003) that activates at least 14 serine/threonine
kinase by phosphorylation of the “T-Loop” threonine localized in their
kinase domain. This implicates the involvement of LKB1 in several
signalling pathways (Shaw RJ, 2004; Lizcano JM 2004).  The first
identified physiological substrate of LKB1was AMPK (AMP-activated
protein kinase), which is a master regulator of cellular energy charge.21
Ten of these 14 AMPK related protein kinases possess an ubiquitin
associated domain (UBA) immediately downstream the kinase catalytic
domain. The UBA domains found in AMPK related kinases do not
interact with polyubiquitin or other ubiquitin-like molecules. Whereas,
the UBA domains appear to play an essential conformational role and are
required for the LKB1-mediated phosphorylation and activation of
AMPK-related kinases. Specifically, UBA domain directly interacts with
the catalytic domain of these enzymes, allowing them to be in a
conformation that can be readily phosphorylated and activated by the
LKB1 complex (Woods A, 2004; Jaleel M, 2006). Thus, it could be
intriguing to investigate whether mutations in the UBA domains might be
present in families with PJS and/or in other cancer patients.
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Figure 4: The LKB1 molecular Pathway
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1.4 Molecular therapeutic target.
The increase of protein synthesis by mTOR has been implicated in the
carcinogenesis of various human tumors by regulating the cell cycle,
apoptosis and angiogenesis through downstream targets such as
cyclooxygenase-2 (COX-2), p53, cyclin D1, c-Myc and hypoxia inducible
factor-1a [5–7]. The signalling pathway that activates mTOR is altered in
many human cancers, and treatment of cancer with mTOR inhibitors has
shown responses in various cancers. [8,9]. (No JH et al. 2009)
Essentially PI3Ks, PDK1, AKT and mTOR are heavily targeted for
therapy in different ways. These proteins are that could be drug target of
cancer cells. In fact cancer cells with the activated pathway will be more
dependent upon this pathway for their survival. (No JH, et al. 2009)
There are currently no approved therapies for PHTS and PJS in clinic.
However, rapamycin, a specific inhibitor of mTORC1, discovered more
then 30 years ago, attracts a renewed interest. Rapamycin (sirolimus is the
official generic name) is a prototypical inhibitor of mTORC1 signalling.
Rapamycin forms a cytosolic complex with FK506 binding protein 12
(FKBP12), which inhibits the catalytic activity of mTOR. (Sabatini DM,
2006). However, the precise mechanism of rapamycin-induced inhibition
of mTORC1 signalling is not completely understood, and at least two
mechanisms of rapamycin action have been proposed. It was shown that
under some experimental conditions FKBP12-rapamycin destabilizes the
interaction of mTOR with raptor, which is required for mTOR activity.
Separate studies demonstrate that the FKBP12- rapamycin complex
suppresses mTORC1 autophosphorylation,  which also may inhibit
mTORC1 activity76 suggesting the possibility that the rapamycin-
dependent mTORC1 inhibition may involve more then one mechanism.
Because mTORC1 signalling is a highly conserved pathway that regulates
protein synthesis and cell growth in all eukaryotes and because of its
activation not only in hamartoma syndromes, but in many types of cancer,
there is a growing interest in rapamycin and its analogs. In 1999
rapamycin was approved by the Food and Drug Administration (FDA) for
the prevention of renal allograft rejection. Currently, clinical studies
demonstrate that rapamycin and its analogs have shown anti-cancer
activity in variety of malignancies. Furthermore, a number of rapamycin
analogs are in preclinical development. Numerous compounds as PI3K,
Akt and mTORC1 inhibitors also have been filed. Currently, the phase II
clinical trial of rapamycin in patients with Cowden syndrome is open for
enrollment at the Warren Grant Magnuson Clinical Center, Maryland
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(NCI, ClinicalTrials.gov Identifier NCT00722449). (Krymskaya1, V.P.
and  Goncharova E. A, 2009) .
PI3K-mTOR signalling also regulates chemokine (C-X-C motif) ligand 1
(CXCL-1), cyclooxygenase-2 (COX-2), and interleukin-8 (CXCL-8) that
enhance tumor metastasis. PI3K and AKT regulate epithelial–
mesenchymal transition (EMT), which is a change allowing tissue
invasion and metastatic potential (Cheng et al., 2008; Onoue et al.2006).
A large body of evidence support that it has a role in tumor promotion,
and accordingly selective COX-2 inhibitors have been shown to be
beneficial in colorectal cancer patients. These results encouraged to
perform a short-term pilot clinical trial in colorectal cancer patients with
celecoxib showing that a subset (2/6) of patients responded to the
treatment with reduced polyposis (Katajisto P, et al. 2006).
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1.5 Aim of the work
The inherited hamartomatous syndromes occur at approximately 1/10th
the frequency of the adenomatous syndromes and account for <1% of
colorectal cancer. However, proper identification of the specific
syndrome has major importance for the affected individual and at-risk
family members as the malignant potential in these autosomal dominant
syndromes is quite high. Although the inherited hamartomatous polyposis
syndromes are less common and less well characterized than the
adenomatous polyposis syndromes, major advances in the molecular
understanding and genetic basis of these syndromes have similarly
needful. The identification of affected patients points to the need for
genetic counseling prior to predictive gene testing for the individual and
at-risk family members. Potentially, as our understanding of these novel
genes accumulates, our ability to diagnose, classify, treat, and hopefully
prevent polyp formation and malignant transformation will improve.
(Schreibman IR 2005). All the evidence indicates that the PI3K/AKT
pathway is a promising target for cancer chemotherapy in hamartomatous
syndromes. Indeed, many companies and academic laboratories have
initiated a variety of approaches to inhibit the pathway at different points.
Therefore, proper diagnosis of tumours with an activated PI3K pathway is
pre-requisite for the use of the targeted therapies (Carnero A., 2010) .
The aim of this study was  the precise molecular characterization, of the
genetic defect and the evaluation of involvement of the molecular
pathway downstream, to better clarify the molecular mechanism and the
potential targeted therapy in patients with hamartomatous poliposys
syndromes.
To better  clarify the molecular background of the PJS families, we have
analyzed the entire coding sequence and splice junctions of the
STK11/LKB1 gene in a series of PJS patients. All patients recruited in
this study showed well-established clinical diagnostic criteria for PJS,
including the characteristic PJS polyps in the gastrointestinal tract and
classical PJS pigmentation; about half of which presented family history
of PJS .
Finally in order to try to understand more specifically the molecular
mechanisms that characterize the onset of PHTS, we have first screened
the PTEN coding region in three italian patients with clinical diagnosis of
PHTS and afterwards, in periferal blood cells of these patients, we have
defined the expression profile of other genes directly related to PI3K/Akt
phatway, as cMYC, COX2, CCND1 and TNFa, or involved in colorectal
cancer onset, as APC.
Materials and Methods
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MATERIALS AND METHODS
2.1 Patients
A total of 9 unrelated patients, exhibiting mucocutaneous pigmentation
and hamartomatous polyposis, were referred by gastroenterologists and
pediatric gastroenterologists to the laboratory, for genetic analysis. The
histological aspects of polyps were unambiguous in all cases.
Characteristic features defining the clinical diagnosis were considered:
presence of pigmentation, polyps localization, histological diagnosis (the
specific phenotypes are listed in Table 2 (see “Results” section). When at
least two patients belonged to the same family, they were considered as
familial cases.
Samples from all families that participated in the study were collected
after informed consent of the participants.
2.2 LKB1/STK11 and PTEN germline point  mutations analysis
Samples of genomic DNA and RNA from affected individuals and at-risk
family members individuals were isolated from peripheral blood
lymphocytes by standard methods. RNA was obtained from peripheral
white blood cells collected with EDTA. We used a combination of 4
techniques to analyze sequence variants within the LKB1 gene: the direct
sequencing of amplified fragments, for point mutations DNA analysis of
the nine exons and flanking intronic sequences; patients without
LKB1/STK11 point mutations were further investigated by Southern blot
analysis and genomic amplification of large fragments for detection of
deletions of all or part of the gene. RT-PCR and quantitative Real-time
RT-PCR techniques were used for the analysis of the LKB1/STK11 gene
at the RNA level.
For PTEN analysis we have performed a qualitative RT-PCR, followed
by  the direct sequencing of amplified fragments, and also the direct
sequencing of genomic DNA fragment in the region where we have found
an alteration in cDNA sequence. Finally quantitative Real-time RT-PCR
assay was performed to evaluate the RNA levels.
Genomic DNA from at least one affected individual per family was PCR-
amplified in eight different genomic regions that covered the entire
coding sequence of the LKB1 gene and all of the splicing junctions. The
oligonucleotide primers used are described in Table 2 and the conditions
for PCR amplification are the following: 94 °C for 5 min, initial
denaturing phase; 33 cycles at 94 °C (30 sec), 60-67 °C (20 sec) 72 °C
S thyroid nodules, presence of polyps in the gastrointestinal tract,
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(45 sec) and 72 °C for 3 min, final extension. Exons 3 and 9 were
amplified as Nested PCR with the following oligonucleotides (the 3a
couple for the first reaction and the 3b couple for the Nested amplification
reaction of the exon 3 and the 9a couple for the first reaction and the 9b
couple for the Nested amplification reaction of the exon 9, respectively,
as reported in Table 2).
Table 2: Oligonucleotides primer used for genomic sequences DNA analysis
Amplification and direct sequencing were also set up to screen the region
coding for the UBA domains of AMPK related protein kinases,
phosphorylated and activated by STK11/LKB1. Each region was PCR-
amplified in one or two fragments; the oligonucleotide primers used are
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described in Table 3 and the conditions for PCR amplification are the
following: 94 °C for 5 min, initial denaturing phase; 33 cycles at 94 °C
(30 sec), 60-67 °C (20 sec) 72 °C (45 sec) and 72 °C for 3 min, final
extension.
Table 3: Oligonucleotides primers used for analysis of the UBA domains of AMPK
related protein kinases
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Amplification of genomic DNA from the PHTS1 patient was performed
in different genomic region of exon 5 of the PTEN gene. The
oligonucleotide primers used are described in Table 4 and the conditions
for PCR amplification are the following: 94 °C for 5 min, initial
denaturing phase; 33 cycles at 94 °C (30 sec), 60-67 °C (20 sec) 72 °C
(45 sec) and 72 °C for 3 min, final extension.
Table 4: Oligonucleotides primer used for PTEN mutation analysis
Sequencing analysis was performed in a 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA). For nucleotide numbering, the first A
of the initiator ATG codon is nucleotide +1 of the STK11/LKB1 mRNA
sequence (GenBank Accession number NM_000455.4); the GenBank
Accession number of the genomic STK11/LKB1 region is: AC_000019.4
The GenBank Accession number of PTEN genomic sequence is: NG-
007466.1. All oligonucleotides were obtained with primer 3 Software
(http://www.genome.%20wi.mit.edu/cgi%20bin/primer/primer3) and
checked with web Basic Local Alignment Search Tool program (BLAST,
NCBI home page http://ncbi.nlm.nih.-%20gov/blast).
The novel mutations were searched for in 100 control samples to exclude
the possibility of a rare polymorphism.
2.3 Qualitative RNA based analysis of patents.
For RNA analysis, we synthesized cDNA with 1 μg of total RNA, 500 ng
of random hexamers, and 1 μl Superscript III reverse transcriptase
(INVITROGEN), in the presence of 4 μl 5X RT buffer, 1 μl DTT (0.1 M)
and 1 mM dNTPs. The reaction was run for 50 min at 42 °C in a 20 μl
reaction volume, heated to 70 °C for 15 min and snapchilled on ice.
For STK11/LKB1 analysis 1 µl of the cDNA was amplified with primers
described in Table 2, that produce three overlapping fragments (1FP–
4RP, 2FP–8RP, 5FP–9RP) covering exons 1–9 of the cDNA. The reaction
was performed as described above: 94 °C for 7 min, initial denaturing
phase; 40 cycles at 94 °C (1 min), 60°C (45 sec) 72 °C (2 min) and 72 °C,
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and a 5-min final extension.
For PTEN analysis 1 µl of the cDNA was amplified were amplified as
Nested PCR with the following oligonucleotides (the PTEN 5’UTR-
1FP/3’UTR-1RP couple for the first reaction and the PTEN 5’UTR-
2FP/3’UTR-2RP couple for the Nested amplification reaction as reported
in Table 5) that cover the entire coding sequence of the gene and all of the
splicing junctions, and produce two fragments of 1815 bp and 1550 bp,
respectively.
The PCR products were analyzed on a 1% agarose gel in trisacetic acid
(TAE)–EDTA standard buffer and visualized by ethidium bromide
staining.
Table 5: Oligonucleotides primer used for RT-PCR analysis
2.4 Quantitative RNA based analysis of patents.
The quantitative RNA real-time assays was performed using the iCycler
iQ Real-Time Detection System BIO-RAD. Amplification was carriedout
in a total volume of 15 μl containing the SYBR Green PCRMaster Mix
1X (BIO-RAD), using 15 ng of cDNA synthesized from poly(A) mRNA.
The real-time PCR reaction was optimized according to the
manufacturer's instructions but scaled down to 15 μl per reaction. The
PCR conditions were standard (iQ™ SYBR Green Supermix) and all
reagents were contained in the standard iQ™ SYBR Green Supermix
(BIORAD). The reactions were: 95 °C for 3 min initial denaturing phase;
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95 °C for 15 s and 60 °C for 1 min. At the end of the PCR, the
temperature was increased from 55 to 95 °C at a rate of 3 °C/min, and the
fluorescence was measured every 10 s to construct the melting curve. A
nontemplate control was run for each assay, and all determinations were
performed at least in triplicate to ensure reproducibility. Synthesis of
expected PCR product was confirmed by melting curve analysis.
Oligonucleotides yielding 100–150-bp-long PCR products at an annealing
temperature of 60 °C were obtained with Primer Express Software
(Applied Biosystems, Foster City, USA) and primer 3
(http://wwwgenome.%20wi.mit.edu/cgi%20bin/primer/primer3), and
checked with web Basic Local Alignment Search Tool program (BLAST,
NCBI home page http://ncbi.nlm.nih.-%20gov/blast).
To measure STK11/LKB1 mRNA level, we selected two couples of
oligonucleotides (reported in Table 2) within exons 1 - 2 and 7 - 8, to
amplify the canonical messenger of the STK11/LKB1 gene.
To analyze PTEN gene mRNA, we used the couple of oligonucleotides
(reported in Table 6) within exons 5 - 6, to amplify the canonical
messenger of the STK11/LKB1 gene
Finally a relative quantization of APC,cMYC,CCNDI,COX-2  and  TGFβ
mRNA level was performed in CS patients (All primers usedare reported
in Tab.6).
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Table 6: Oligonucleotides primer used for  real-time analysis
The relative expression of the target transcript was calculated with the
comparative Ct method (Applied Biosystems User Manual) using a
cDNA fragment from the glucuronidase (GUS) housekeeping gene as
control.
2.5 Amplification analysis of genomic DNA
Genomic PCR reaction was performed for the analysis of region
encompassing exons from 2 to 8 of the LKB1 gene (from nucleotide
12515 to nucleotide 17436). The first product consists of a 4200 bp long
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fragment including the LKB1 genomic region from exon 2 to exon 8. The
second and third products consist of two fragments, of 2160 bp (from
exon 2 to exon 4) and of 2000 bp long (from exon 5 to exon 8),
respectively. The oligonucleotide primers used are described in Table 5
and the conditions for PCR amplification are the following: 94 °C for 7
min, initial denaturing phase; 40 cycles at 94 °C (1 min), 60°C (45 sec) 72
°C (5 min) and 72 °C, and a 20-min final extension.
To analyze the genomic alteration of patient number 2, carrier of exons 2
and 3 skipping at the RNA level, we performed a set of PCR reactions
encompassing genomic region between exons 1 to 4. This region was
amplified in 13 PCR fragments, using the same reverse oligonucleotides
in each reaction (IVS 3RP in Table 7) and different forward
oligonucleotides spaced each other by about 1000 bp. The oligonucleotide
primer sequences are described in Table 2 and the PCR conditions were
the following: 95 °C for 2 min, initial denaturing phase; 10 cycles at 95
°C (1 min), 66°C to 64 °C with a decrement of 0.2°C each cicle (30 sec),
72 °C (3 min), 30 cycles at 95 °C (1 min), 64 °C (30 sec), 72 °C (3 min)
and 72 °C 5-min, final extension. The PCR products were analyzed into a
1% agarose gel in trisacetic acid (TAE)–EDTA standard buffer and
visualized by ethidium bromide staining.
Table 7: Oligonucleotides primer used to analyse genomic alteration of patient number 2
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2.6 In silico analysis.
The nucleotide sequences of genomic LKB1 region (NCBI
NC_000019.9) were analyzed with the RepeatMasker program using the
default settings (exon.cshl.org/ESE/). This is a program that screens DNA
sequences for interspersed repeats and low complexity DNA sequences.
The output of the program is a detailed annotation of the repeats that are
present in the query sequence as well as a modified version of the query
sequence in which all the annotated repeats have been masked (default:
replaced by Ns). Sequence comparisons in RepeatMasker are performed
by the program cross-match, an efficient implementation of the Smith-
Waterman-Gotoh algorithm developed by Phil Green (A.F.A. Smit, R.
Hubley & P. Green RepeatMasker at http://repeatmasker.org).
2.7 Southern blot analysis
Genomic Southern blot was performed after endonuclease digestion of
genomic DNA from PJS patients and healthy non affected controls with
BamHI restriction enzyme; afterwards it was probed with a cloned cDNA
fragment that comprised the entire coding region of LKB1/STK11 gene.
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RESULTS
3.1 LKB1/STK11 and PTEN germline point  mutations analysis
We have analyzed the disease-causing mutations in 9 unrelated PJS and 3
PHTS patients from Italy. All patients showed the classical phenotype
associated to these two disease; multiple hamartomatous polyps in the
gastrointestinal tract and mucocutanoeus pigmentation for PJS and
hamartomatous gastric or colonic polyps, colon cancer, penis macules for
PHTS. Sequencing of the 9 exons and the exon–intron junctions of
LKB1/STK11 gene led to the identification of 6 unique pathologic
germline mutations. (Table 8). According to the human gene mutation
database (http://archive.uwcm.ac.uk/uwcm/mg/hgmd/search.html), 2 are
known and 3 are novel germline LKB1 point mutations. Of these one is
located in exon 1, one in exon 4 and three in exon 6. The sixth mutation
consists in an intragenic deletion that eliminates exons 2 and 3 of the
gene.
Two of the point mutations are frameshift mutations: the c.169-170insG
mutation, that consists in an insertion of a G nucleotide at position 169-
170 and the c.842delC mutation, that consists in a C nucleotide deletion at
position 842. Both mutations create a premature stop codon respectively
105 and 5 codons below.
The mutation named c.580GA is a missense mutation in exon 4, that
consists in a G to A substitution at position 580, causing the change of an
Aspartic Acid in an Asparagine residue at position 194.
The last two germline point mutations identified, previously not described
in literature, are two in frame micro-deletions localized in exon 6. The
first, called c.747-749delCAC determines the deletion of the Threonine
residue at position 250; the second, named c856-858delCTC determines
the deletion of the Leucine residue at position 286. Both mutations
modify the catalitic domain (kinase domain) of the LKB1/STK11 protein,
characterized by highly conserved residues among different species
(human, mouse, xenopus), likely altering the correct protein function.
These two in frame deletion are not common polymorphisms, since they
were not detected in the DNA of the 100 normal Caucasians controls.
In the family of the patient carrier of the c.747-749delCAC mutation, the
molecular diagnosis was performed in six relatives, two of whom were
affected and four apparently healthy individuals. This mutation always
segregates with the disease in this family; furthermore, we were be able to
carry out the presymptomatic diagnosis in the two young proband’s at-
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risk sons (of eight and seven years old respectively), both resulted carriers
of the deletion.
We found about the same prevalence of LKB1/STK11 mutations both in
sporadic PJS patients (66.7%; 2 out of 3) and familial cases (60%; 3 out
of 5).
No mutations were identified in the region coding for UBA domain of the
AMPK related protein kinases. Moreover, two patients, negative for
LKB1/STK11 gene mutation, proved to be carriers of two intronic single
nucleotide substitutions not reported in database (NCBI:
http://www.ncbi.nlm.nih.gov/snp) with unknown meaning (the
c.983+55CT in MARK2 gene and the c.968+32GA in BRSK2 gene,
in patient number 8; the c.1007+43CA in MARK4 gene and the
c.972+57CT in SIK gene, in patient number 5).
In patient PHTS1 we found a missense mutation named c.406TC in
exon 5 of PTEN gene, this mutation just described in literature before that
determines the aminoacidic change of cysteine residue136 in arginine
(Kubo Y, et al. 2000).
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Table 8: Clinical phenotype and mutation spectrum of Italian PJS and PTHS patients
studied. F: familial cases; S: sporadic cases; N.F.: mutation not found; the bold character
indicates the novel mutations.
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3.2 Qualitative RNA based analysis of patents.
We examined LKB1/STK11 mRNAs from peripheral blood lymphocytes
of four PJS patients negative for germline LKB1/STK11 point mutations
and three healthy individuals, as controls. Using the RT-PCR technique
we amplified three fragments encompassing exons 1–4, 2–8 and 5–9,
respectively. In addition to the normal sized fragment, which was
observed in all samples tested, a low-molecular-weight fragment was
detected in one affected individual (Fig 5a  line number 3). Sequence
analyses showed in Fig. 5b of the expected and low-molecular-weight
fragment revealed the skipping of exons 2 and 3 in the shorter fragment.
The deletion of exons 2 and 3 results in a novel exon 1/4 connection, that
maintains the reading frame and encodes for a protein lacking  a region
that includes part of the kinase domain. No other mRNA alterations were
detected in all samples analysed.
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38
Figure 5: cDNA analysis of STK11/LKB1 coding region.
a) Gel electrophoresis of the amplified products by RT-PCR technique; numbers from 1
to 7 correspond to PJS patients as described in table 1. The arrow indicates a PCR
product of molecular weight shorter than expected. N.C.: PCR negative control; S.M.:
DNA molecular weight marker.
b) Sequence analysis of the normal sized (above) and low-molecular weight (below) RT-
PCR products. The arrows indicate the nucleotides at the canonical junction between
exon 1 and exon 2 (above) and at the novel junction between exon1 and exon 4 (below).
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PTEN analysis was performed amplifying the whole coding region of the
gene in a unique fragment, using RT-PCR reaction has revelled only  the
normal sized fragment, which was observed in all samples tested. This
result exclude the presence of splicing alterations or intragenic deletions
in these patients. Direct sequencing of amplified fragments reveded in
patient PHTS1 a TC transversion at position 406. These missense
mutation, called c.406TC  determines the aminoacidic substitution of
the  C 136 with the R. The nucleotide sequence accession number for this
messenger region is: NM_000314.4. No other sequence alterations were
detected in all samples analysed.
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Figure 6: cDNA analysis of PTEN coding region: a) Gel electrophoresis of the
amplified products by RT-PCR technique; b) Sequence analysis of the RT-PCR
products.
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3.3 Quantitative RNA based analysis of patients.
Finally quantitative Real-time RT-PCR assay was performed to evaluate
the RNA levels. To verify whether quantitative mRNA alterations were
responsible for PJS and for (PHTS) in our patients, we performed
quantitative Real-Time PCR analysis on cDNA from peripheral blood
lymphocytes. Fig. 7a shows the relative expression of the LKB1 transcript
containing exons 1–2 (columns 1) and of the LKB1 transcript containing
exons 7-8 (columns 2), normalized versus the glucuronidase (GUS)
transcript. We found a quantitative mRNA alteration in patient number 2,
in whom the LKB1 1–2 transcript fragment, but not the LKB1 7-8
transcript fragment, was significantly down-expressed (the decrement was
0.5-fold compared to the healthy control).
Fig. 7b shows the relative expression of the PTEN transcript containing
exons 5–6, normalized versus the glucuronidase (GUS) transcript. We
found a quantitative mRNA alteration in both patients  negative  for  the
presence  of  mutation  in  the  PTEN  gene  coding  region, with a
relative espression of 0.3 and 0.1  fold  compared  with  the healty
controls. As expected from previous results, it is not observed any
change in the PTEN gene expression level.
Results
42
Figure 7:  Real-time PCR quantification analysis. Relative expression, calculated with
the comparative Ct method, of two STK11 transcript fragments spanning the junctions
between exons 1-2 and exons 7-8, respectively, b) of PTEN gene fragments spanning the
junctions between exons 5-6,compared to glucuronidase transcript fragment. Patients
numbering corresponds to that adopted in Table 2.
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Relative expression analysis, performed in all the three PHTS patients,for
the four genes related to the molecular pathway PI3K/AKT has shown an
increment of expression for COX-2,CCD1 and TNFα genes, in all PHTS
patients, whereas APC transcript fragment, was down-expressed (as show
in fig.8)
Figure 8: Relative expression of  four PI3K/AKT pathway genes calculated with the comparative
Ct method, compared to glucuronidase transcript fragment. Patients numbering
corresponds to that adopted in Table 2.
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3.4 Amplification analysis of genomic DNA
No qualitative DNA alterations were detected using genomic
amplification analysis, as described the in method section. Gel
electrophoresis of amplified fragments followed by etidium bromide
staining evidences only products of expected size (data not shown).
According to the quantitative mRNA data, PJS patient number 2, carrier
of exons 2 and 3 deletion at the RNA level, resulted heterozygous at
polymorphic marker localized in exon 4 of the LKB1 gene, thus
excluding a whole-gene deletion. However, we have been unable to detect
point mutations at either the splice sites or the neighboring intronic
sequences (up to 40 bases) of the two exons (2 and 3) at the genomic
DNA level, suggesting the presence of an intragenic deletion
encompassing exons 2 and 3. To verify this hypothesis we have amplified
this region with specific oligonucleotides, as described in the methods
section, and have characterized the precise breakpoints of this mutation.
Abnormal fragment products were identified in patient number 2 but not
in the healthy control subjects, of about 1000, 2000 and 3000 bp long
respectively, using primer pairs IVS1D-FP/IVS3-RP, IVS1E-FP/IVS3-RP
and IVS1F-FP/IVS3-RP. No amplified fragment was obtained by using
several forward primers within IVS1 and IVS2 and reverse primer (IVS3-
RP) (Fig. 9a).
As shown in Figure 9b, sequence analysis of the amplified fragment
IVS1F-FP/IVS3-RP revealed the loss of a genomic region of about 7000
bp long. We have characterized the breakpoints of this region within two
sequences of 12 bp that share 100% homology, located in intron 1 from
nucleotide 6999 to nucleotide 7010 and in intron 3 from nucleotide 73987
to nucleotide 13998.  The two 12 bp long sequences are located within
two sequences of 26 bp that differ from each other only by one nucleotide
(96% homology) (Fig. 9b). The nucleotide sequence accession number for
this genomic region is: NC_000019.9.
To confirm the mutation c.406TC detected in PHTS patient 1, we had
performed a genomic amplification analysis for exon 5 of PTEN gene.
The subsequently sequence analysis had confirmed the presence of the
mutation also in the genomic region of gene.
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Figure 9: Molecular characterization of the STK11/LKB1 intragenic deletion.
a) Gel electrophoresis of the amplified products by genomic PCR performed on patient
number 3. P.: patient; N.C.: PCR negative control; S.M.: DNA molecular weight marker.
b) Sequence analysis of the amplified product obtained with primer pair IVS1-F-FP and
IVS3-RP. Boxed sequence corresponds to the twelve nucleotides repeated both at the 5’
and 3’ breakpoints sharing 100 % of homology and representing the novel genomic
connection produced by the deletion event. A schematic representation of the primer
pairs position on the gene, used for the deletion breakpoints characterization, is shown
above the electropherograms. Bold arrows indicate the genomic region involved in the
deletion and the genomic nucleotides position involved in the novel genomic junction,
referred to GenBank sequence with accession number: NC_000019.9.
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3.5 In silico analysis.
Using the Repeat Masker program, the 5’ and 3’ breakpoints of this 7 kb
deletion were found to lie within the core of two Alu sequences (26 bp) of
the complete Alu elements (both AluY subfamily), (Fig. 10B, Table 9).
Furthermore, a fragment of 400 bp, homologous to the 3’ region of long
interspersed nuclear element L1 (L1MB5), is located immediately
downstream of 5’ breakpoint of the deletion. A 266-bp fragment,
homologous to the 3’ region of another L1 repeat (L1MB7), is located
about 3100 bp downstream of the 5’ breakpoint. In addition, there are
other 16 Alu repeat elements and 2 simple repeats interspersed within the
genomic region including introns 1-3; the Repeat Masker program
recognizes a total of 18 Alu sequences, 3 L1 sequences and 6 simple
sequences (Table 9).
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Figure 10: Schematic representation of the intragenic deletion
a) Repetitive elements present in the genomic region from exons 1–4 of the
STK11/LKB1 gene and a diagram (below) of the deletion are shown.  The arrow
indicates the novel genomic junction.
b) Sequence of Alu element present at the 5’ and 3’ breakpoints (5’ BP, 3’ BP, of part a);
boxed nucleotides represent the core sequence of Alu elements.
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Alu repeat
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Table 9: Repetitive sequences in the STK11/LKB1 genomic region.
LINE: long interspersed nuclear element; SINE: short interspersed nuclear element.
Modified from RepeatMasker program (exon.cshl.org/ESE/)
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3.6 Southern blot analysis.
All LKB1/STK11 mutation-negative probands were analyzed by Southern
blot to detect deletions that would not be revealed by a combination of
genomic amplification and RNA based analysis. No deletions were
detected, since all fragments were of expected size (data not shown).
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DISCUSSION
Recognition and correct differential diagnosis of the hamartomatous
polyposis syndromes, although they are quite rare,  is essential because
patients have a high lifetime risk of gastrointestinal and extraintestinal
carcinoma and their first-degree relatives have high risk of recurrence of
the sindrome.
Inactivating mutations in LKB1 have been detected in 18–70% of the PJS
patients (Lizcano JM et al. 2003) and the absence of detectable LKB1
mutations could be explained by the existence of an alternative LKB1
gene inactivation mechanism that remains undiscovered by conventional
screening methods or, alternatively, by genetic heterogeneity. Some
families have been reported to be clearly unlinked to the LKB1 locus
(Woods A, et al. 2003; Jaleel M, et al. 2006)  and linkage analysis has
previously suggested a second locus on chromosome 19q13.4.
Furthermore, a t(11;19)(q13;q13.4) translocation in a small bowel PJS
polyp has been found, although no mutations within the genes in this
region have yet been reported.21,24,25 Candidates for the second PJS locus
might be genes known or suggested to interact with the LKB1 either by
direct association with LKB1 or by their own function; three such genes,
LIP1, MO25a, and STRAD have been screened with negative results.
The mutation screening strategy used in our study was targeted to detect
STK11/LKB1 and PTEN genetic alterations as point mutations, large
genomic rearrangements and mutations in the regulatory domains of the
gene, leading to qualitative or quantitative alterations of its transcript.
Despite a detailed molecular genetic analysis, we observed germline
STK11/LKB1 mutations in 6 out of 9 patients (about 66.7%), thus
indicating that such a novel mechanism affecting STK11 gene expression
in PJS patients is yet to be investigated; however, genetic heterogeneity in
PJS could not be excluded.
Using the strategy described above we have characterized the breakpoints
of the LKB1/STK11 intragenic deletion found in one PJS patient and have
suggested the mechanism probably involved. This rearrangement is most
likely an Alu-Alu homologous recombination event that deletes about 7
kb of the LKB1 genomic region encompassing exons 2 and 3 (Fig. 3C).
Two 26 bp core sequences of two Alu elements (both AluY sequences),
showing a 96% homology, are localized at the 5’ and 3’ end of the
breakpoints, respectively. This sequence, could itself act as a recombinase
(Fig. 3C).
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Alu-mediated homologous recombination is a mechanism well
documented so far, (Kolomietz E et al. 2002, Grover D, 2004) however it
is the first evidence that this mechanism is involved in the STK11/LKB1
gene rearrangements. Since the average frequency of Alu elements along
the human genome is estimated to be one element every 4 kb, the region
spanning the 7 kb deletion (including introns from 1 to 3 of the LKB1
gene), shows an over-representation of complete Alu elements (Fig. 3C).
Seventeen Alu elements are detected in this region by using in silico
analysis, which corresponds to more than one element every 1 kb in this
14.5-kb region (Table 3).
The over-representation of Alu elements indicates that this is a region of
DNA instability; thus, it is not surprising that several intragenic
rearrangements involving this region have been reported so far.
Intriguingly, genomic sequence of chromosome 19 from GeneBank
position 1203099 to 1230861 shows the presence of Alu elements at the
genomic regions involved in the intragenic deletions in most of the cases
so far described. The intragenic deletions described include the exon 1
(encompassing 5’UTR region and exon 1), exons from 1 to 10, exons 2
and 3, exons from 2 to 10, exons 4 and 5 and the exon 8; 6-8 in parallel Alu
elements are localized at chromosomal region encompassing the 5’UTR,
IVS1, IVS3, IVS8 and the 3’UTR regions of the STK11/LKB1 gene;
furthermore, repeated sequences, as Simple-repeat and GC-rich Low-
complexity sequences, are included in the region corresponding to
5’UTR, IVS1, IVS9 and 3’UTR. Genomic sequence also reveals two
incomplete L1 elements near the deletion, about 490 bp and 3.3 kb
downstream the 5’ breakpoint (Fig. 3B, Table 3), but it is still unclear
whether it could play an active role in the rearrangement, since the
homologies are with the 3’ untranslated region of L1 elements.31
The LKB1 allele containing this intragenic deletion code for a LKB1
mRNA that lacks exons 2 and 3 and maintains the protein reading frame;
the translated product should results in a protein lacking the portion of
LKB1 catalytic domain. Noteworthy, the clinical manifestation is that of
severe phenotype with very early onset age of the disease (5 years).
According to the literature data, our results suggest that large intragenic
rearrangements could intervene at the LKB1 locus and that their
incidences have probably been underestimated by mutation screening
strategies based on molecular biology techniques.
However, we observed germline STK11 mutations in about 66.7% of
affected subjects, although it is not possible to exclude that genetic locus
heterogeneity exists in PJS manifestations. Because of over-
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representation of Alu elements involving this region, in our opinion is
reasonably to hypothesize that Alu-mediated homologous recombination
could give rise to several intragenic rearrangements, as translocations or
inversions, not always detectable using classical molecular biology
techniques. These rearrangements could in part explain the remaining PJS
cases without identified molecular alterations.
Finally, we investigate the hypothesis that mutations in the ubiquitin-
associated domain (UBA) of the AMP-related kinase genes, might be
present in families with PJS. The AMPK related kinases are activated
following phosphorylation of their T-loop threonine residue by the LKB1
complex32 and nine of these contain an UBA domain immediately C-
terminal to the kinase catalytic domain; this domain allows LKB1-
induced phosphorylation and activation. No mutations were identified in
the region coding for UBA domain of the AMPK related protein kinases;
however, two of the analyzed patients resulted carrier each of two intronic
single nucleotide substitutions not reported in database (described in
result section). Additional studies are necessary to shed light on their
meaning.
Concerning the molecular analysis PHTS patients, unfortunately we could
analyze a lower series o f patients, so we have identified a missense
mutation in one of the three PHTS patients screened. However, our
casuistry have to related to the rarity of the disease, which appears to be
underestimated, because the PHTS syndromes presents a incomplete and
variable penetrance, that can complicate the clinical diagnosis.
In both of the PHTS patients negative for the presence of mutation in
gene coding region, the quantitative analysis showed a marked decrease
in the levels of messenger. We have excluded the possibility of a deletion
of the entire gene in these patients due to the presence of heterozygous
polymorphisms, and the DNA real-time quantitative analysis. So this
decrease is probably due to other mechanisms of inactivation in the PTEN
gene, as alterations in the promoter region or the involvement of modifier
genes (Zhou XP, et al. 2003).
The next step of our study was to test the effects of PTEN inactivation on
the expression of several genes regulated by PI3K/AKT molecular
pathway or otherwise involved in CRC development.
PTEN is a tumour-suppressor gene that has attracted significant interest
given its high mutation frequency in human cancers and its roles in
apoptosis/proliferation via negative regulation of AKT/PKB activity
(Downward, 2004; Parsons, 2004). Consistent with the direct protein-
protein interactions that regulate p53 function (Freeman et al., 2003; Lei
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et al., 2006), PTEN mutation in individuals with Cowden Disease results
in cancer predisposition (Liaw et al., 1997) associated with cutaneous
hyperkeratosis (Fistarol et al., 2002), suggesting that roles in keratinocyte
differentiation can be added to PTEN activities that are essential for
normal development. In transgenic mice, Pten hetrozygotes (Stambolic et
al., 2000) or conditional knockouts (Li et al., 2002; Suzuki et al., 2003)
exhibit neoplasia associated with increased anti-apoptotic AKT activities,
cell migration/adhesion anomalies (Subauste et al., 2005) and cell cycle
control failure (Di Cristofano et al., 2001). In addition, recent models
demonstrate that PTEN via PI3K–Akt signalling, cooperates with Wnt to
increase -catenin signaling during inflammation. Instead,  further recent
study  has linked this interaction with the inflammatory process, in fact
inhibition of PI3K signaling in interleukin (IL)-10 knockout (IL-10 β-/β-)
mouse colitis abrogated β -catenin signaling, crypt proliferation, and
dysplasia (Lee G, et al 2010). Furthermore evidence shows a connexion
between AKT and TNF-NF-kB pathway. In fact NF-κB increases Akt
activity as evidenced by increased phosphorylated form of Akt and its
downstream target GSK-3β. These data suggest that the increased Akt
activity is facilitated by reduction in PTEN expression. NF-κB-induced
activation of Akt also suggests an interesting positive feedback loop,
where activated Akt further facilitates NF-κB activation. Such a feedback
loop may augment Akt activity in tumors and increase tumor growth and
invasion. The NF-κB inhibitor IκB-α is degraded rapidly upon TNF-α
stimulation and then resynthesized after NF-κB stimulation. One
implication of the role of IκB-α as a temporal regulatory switch to
turn off NF-κB by resynthesis of IκB-α is the hypothesis that some NF-
κB-responsive genes are activated with a short pulse of NF-κB, whereas
other genes need longer exposure to activate transcription. The bimodal
temporal signal activation of NF-κB/IκB-α to up-regulate the two classes
of NF-κB target genes was demonstrated for NF-κB-induced activation of
the chemokine interleukin-10. These findings underlying the interaction
between PTEN/PI3K/Akt and NF-κB at the level of transcription and
offer one possible explanation for increased tumorigenesis and
inflammation in systems where NF-κB is chronically activated. (Kim S, et
al. 2004).
The results of our analysis, performed on mRNA of the three CS patients
and two healthy controls extracted from peripheral blood lymphocytes,
showed in previous section, is according to this hypothesis. In fact we
have found a sensible increase in mRNA levels of COX-2,CCD1 and
TNFα genes whereas decrease expression of APC gene in all PHTS
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patients.
Our data represent the first evidence of a PI3K/Akt pathway deregulation
in periferal blood cells of PHTS patients that probably determine a pro
inflammation activation. Knowledge of specific molecular pathways
constitutively deregulated in this syndrome could be helpful in optimizing
molecular targeted therapy and preventative care. Otherwise the data
suggests the interesting possibility of use these PI3K/Akt pathway
downstream genes as molecular markers that could support a more
precise and rapid diagnosis of  PHTS syndromes.
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